Novartis AG
FACTOR XI ANTIBODIES AND METHODS OF USE
Last updated:
Abstract:
The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI ("Factor XIa"), and pharmaceutical compositions and methods of treatment comprising the same.
Status:
Application
Type:
Utility
Filling date:
6 Oct 2021
Issue date:
26 May 2022